ABCAM Plc Directorate Change (0353G)

TIDMABC

RNS Number : 0353G

ABCAM Plc

03 August 2016

3 August 2016

ABCAM PLC

("Abcam" or "the Company")

Directorate Changes

Cambridge UK: Abcam plc (AIM: ABC), a global leader in the supply of life science research tools, announces that Non-Executive Directors, Dr Anthony Martin and Mr Michael Ross, having both served a period of approximately 5 years on the Board, gave notice yesterday that they will not stand for re-election at Abcam's Annual General Meeting on 2 November 2016 and will step down from their positions on the Board of Directors with effect from 31 October 2016.

Murray Hennessey, Chairman, commented:

"I would like to thank both Tony and Michael for the significant roles they have played during their service on the Board of Abcam. Their insight and support have been extremely valuable and we wish them well in their future endeavours."

##Ends##

For further information, please contact:

 
                                      + 44 (0) 1223 
Abcam                                  696 000 
Alan Hirzel, Chief Executive 
 Officer 
 Jeff Iliffe, Chief Financial 
 Officer 
 Julia Wilson - Investor Relations 
 
  J.P.Morgan Cazenove - Nominated     + 44 (0) 20 7742 
  Advisor & Corporate Broker           4000 
James Mitford / Christopher Cargill 
                                      + 44 (0) 20 3727 
  FTI Consulting                       1000 
Ben Atwell / Brett Pollard / 
 Natalie Garland-Collins 
 

Notes for editors:

About Abcam plc

As an innovator in reagents and tools, Abcam's purpose is to serve life science researchers globally to achieve their mission, faster. Providing the research and clinical communities with tools and scientific support, the Company offers highly validated biological binders and assays to address important targets in critical biological pathways.

Already a pioneer in data sharing and ecommerce in the life sciences, Abcam's ambition is to be the most influential company in life sciences by helping advance global understanding of biology and causes of disease, which, in turn, will drive new treatments and improved health. Two-thirds of the world's 750,000 life science researchers use Abcam's affinity binders, reagents, biomarkers and assays and the Company's products are mentioned in over 20,000 of the 56,000 peer-reviewed papers published each year in the life sciences.

By actively listening to and collaborating with researchers, the Company continuously advances its portfolio to address their needs. A transparent programme of customer reviews and datasheets, combined with an industry-leading validation initiative, gives researchers increased confidence in their results.

Abcam's ten offices are located in the world's leading life science research hubs, enabling local services and multi-language support. Founded in 1998 and headquartered in Cambridge, UK, the Company sells to more than 100 countries. Abcam was admitted to AIM in 2005 (AIM: ABC).

To find out more, please visit www.abcam.com and www.abcamplc.com

Forward looking statement

This announcement, including any information included or incorporated by reference in this announcement, may contain forward-looking statements (including words such as "believe", "expect", "estimate", "intend", "anticipate" and words of similar meaning) which are based upon current expectations and assumptions regarding anticipated developments and other factors affecting the Abcam Group. All statements other than statements of historical facts may be forward-looking statements and should not be treated as guarantees of future performance. These forward-looking statements involve risks and uncertainties, many of which are beyond the control of the Abcam Group, and there are important factors that could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These forward-looking statements speak only as at the date of this announcement and accordingly undue reliance should not be placed on such statements. The Abcam Group does not assume any obligation to, and does not intend to, revise or update these forward-looking statements, except as required pursuant to applicable law.

This information is provided by RNS

The company news service from the London Stock Exchange

END

BOAFMGGRDZRGVZM

(END) Dow Jones Newswires

August 03, 2016 02:01 ET (06:01 GMT)